{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Simpson EL"],"funding":["NCATS NIH HHS","Eli Lilly and Company"],"pagination":["531-538"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9804170"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["187(4)"],"pubmed_abstract":["<h4>Background</h4>The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) is a standardized severity assessment for use in clinical trials and registries for atopic dermatitis (AD).<h4>Objectives</h4>To investigate the reliability, validity, responsiveness and within-patient meaningful change of the vIGA-AD.<h4>Methods</h4>Data were analysed from adult patients with moderate-to-severe AD in the BREEZE-AD1 (N = 624 patients; NCT03334396), BREEZE-AD2 (N = 615; NCT03334422) and BREEZE-AD5 (N = 440; NCT03435081) phase III baricitinib clinical studies.<h4>Results</h4>Across studies, test-retest reliability for stable patients showed moderate-to-good agreement [range of Kappa values for Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD), 0·516-0·639; for Ec"],"journal":["The British journal of dermatology"],"pubmed_title":["The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis."],"pmcid":["PMC9804170"],"funding_grant_id":["N/A","UL1 TR001863"],"pubmed_authors":["Paller AS","Sun L","Bissonnette R","Eichenfield LF","Reich K","Thyssen JP","Nunes FP","Simpson EL","DeLozier AM","Doll H","King B","Silverberg JI"],"additional_accession":[]},"is_claimable":false,"name":"The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.","description":"<h4>Background</h4>The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) is a standardized severity assessment for use in clinical trials and registries for atopic dermatitis (AD).<h4>Objectives</h4>To investigate the reliability, validity, responsiveness and within-patient meaningful change of the vIGA-AD.<h4>Methods</h4>Data were analysed from adult patients with moderate-to-severe AD in the BREEZE-AD1 (N = 624 patients; NCT03334396), BREEZE-AD2 (N = 615; NCT03334422) and BREEZE-AD5 (N = 440; NCT03435081) phase III baricitinib clinical studies.<h4>Results</h4>Across studies, test-retest reliability for stable patients showed moderate-to-good agreement [range of Kappa values for Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD), 0·516-0·639; for Ec","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-28T06:20:47.832Z","creation":"2025-04-06T09:02:56.317Z"},"accession":"S-EPMC9804170","cross_references":{"pubmed":["35442530"],"doi":["10.1111/bjd.21615"]}}